The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study
Open accessAbstract
BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive skin cancer with a recurrence rate of >40%. Of the 2000 MCC cases per year in the United States, most are caused by the Merkel cell polyomavirus (MCPyV). Antibodies to MCPyV oncoprotein (T‐antigens) have been correlated with MCC tumor burden. The present study assesses the clinical utility of MCPyV‐oncoprotein antibody titers for MCC prognostication and surveillance. METHODS: MCPyV‐oncoprotein antibody detection was optimized in a clinical laboratory. A cohort of 219 patients with newly diagnosed MCC were followed prospectively (median follow‐up, 1.9 years). Among the seropositive patients, antibody titer and disease status were serially tracked. RESULTS: Antibodies to MCPyV oncoproteins were rare among healthy individuals (1%) but were present in most patients with MCC (114 of 219 patients [52%]; P < .01). Seropositivity at diagnosis independently predicted decreased recurrence risk (hazard ratio, 0.58; P = .04) in multivariate analyses adjusted for age, sex, stage, and immunosuppression. After initial treatment, seropositive patients whose disease did not recur had rapidly falling titers that became negative by a median of 8.4 months. Among seropositive patients who underwent serial evaluation (71 patients; 282 time points), an increasing oncoprotein titer had a positive predictive value of 66% for clinically evident recurrence, whereas a decreasing titer had a negative predictive value of 97%. CONCLUSIONS: Determination of oncoprotein antibody titer assists in the clinical management of patients with newly diagnosed MCC by stratifying them into a higher risk seronegative cohort, in which radiologic imaging may play a more prominent role, and into a lower risk seropositive cohort, in which disease status can be tracked in part by oncoprotein antibody titer. Cancer 2017;123:1464–1474. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
Feng, H., Shuda, M., Chang, Y., & Moore, P. S. (2008) · Science · doi:10.1126/science.1152586 · Cited by 3,208
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Self-citation
Cited by
Becker, J. C., Stang, A., DeCaprio, J. A., Cerroni, L., Lebbé, C., Veness, M., & Nghiem, P. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.77 · Cited by 645
Self-citationMerkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Blitzblau, R., Bowen, G. M., Contreras, C. M., Daniels, G. A., Decker, R., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0055 · Cited by 319
Self-citationThe biology and treatment of Merkel cell carcinoma: current understanding and research priorities
on behalf of the International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group, Harms, P. W., Harms, K. L., Moore, P. S., DeCaprio, J. A., Nghiem, P., Wong, M. K. K., & Brownell, I. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0103-2 · Cited by 316
Self-citationNeoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial
Topalian, S. L., Bhatia, S., Amin, A., Kudchadkar, R. R., Sharfman, W. H., Lebbé, C., Delord, J.-P., Dunn, L. A., Shinohara, M. M., Kulikauskas, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00201 · Cited by 280
Self-citation
Metadata
- Authors
- Paulson, K. G., Lewis, C. W., Redman, M. W., Simonson, W. T., Lisberg, A., Ritter, D., Morishima, C., Hutchinson, K., Mudgistratova, L., Blom, A., Iyer, J., Moshiri, A. S., Tarabadkar, E. S., Carter, J. J., Bhatia, S., Kawasumi, M., Galloway, D. A., Wener, M. H., & Nghiem, P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-12-07
- Volume
- 123
- Issue
- 8
- Pages
- 1464-1474
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2560846260
- Cited by
- 188
- References
- 2
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. https://app.cochat.ai/papers/10.1002/cncr.30475
- The paper
- Paulson, K. G., Lewis, C. W., Redman, M. W., Simonson, W. T., Lisberg, A., Ritter, D., Morishima, C., Hutchinson, K., Mudgistratova, L., Blom, A., Iyer, J., Moshiri, A. S., Tarabadkar, E. S., Carter, J. J., Bhatia, S., Kawasumi, M., Galloway, D. A., Wener, M. H., & Nghiem, P. (2017). Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer. https://doi.org/10.1002/cncr.30475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.